<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01996943</url>
  </required_header>
  <id_info>
    <org_study_id>12-08579</org_study_id>
    <secondary_id>1R01AA022222-01</secondary_id>
    <nct_id>NCT01996943</nct_id>
  </id_info>
  <brief_title>The HOLIDAY (HOw ALcohol InDuces Atrial TachYarrhythmias) Study</brief_title>
  <acronym>HOLIDAY</acronym>
  <official_title>Investigating the Effects of Ethanol on Atrial Fibrillation Susceptibility and Pathogenesis</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, San Francisco</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Alcohol Abuse and Alcoholism (NIAAA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, San Francisco</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Atrial fibrillation (AF) is the most common sustained arrhythmia in the United States and it&#xD;
      has been associated with ethanol use. Understanding how ethanol affects the electrical&#xD;
      properties of the heart and induces AF has important public health implications. The&#xD;
      objective of this research is to investigate the mechanistic relationship between ethanol and&#xD;
      atrial fibrillation in humans by performing a placebo controlled study looking at the&#xD;
      electrical properties of the heart in patients receiving intravenous ethanol or placebo. The&#xD;
      investigators hypothesize that ethanol increases the susceptibility of human myocardium to&#xD;
      atrial fibrillation through electrophysiologic changes in the atrial myocardium in the acute&#xD;
      setting.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The purpose of this study is to look for changes in the electrical properties of heart that&#xD;
      may be caused by ethanol (commonly referred to as alcohol) and specifically how ethanol may&#xD;
      trigger episodes of the most common abnormal heart rhythm, atrial fibrillation (AF). This&#xD;
      study will demonstrate the mechanism of ethanol induced atrial fibrillation and clarify the&#xD;
      health effects of one of the worlds' most popular drugs (ethanol). With this understanding,&#xD;
      physicians may be able to better identify those patients most at risk for ethanol induced AF&#xD;
      and target public health campaigns towards this vulnerable population.&#xD;
&#xD;
      Patients in this study will undergo an electrophysiologic study both prior to and after&#xD;
      receiving either an ethanol or placebo infusion. This electrophysiology study will measure AF&#xD;
      inducibility (the primary outcome), left and right atrial conduction times, and the atrial&#xD;
      effective refractory period in multiple locations (AERP). The changes in the conduction times&#xD;
      and AERPs (before and after study drug infusion) will be recorded as secondary outcomes.&#xD;
&#xD;
      About 100 people will participate in this study. 50 people will be randomized to receive&#xD;
      intravenous ethanol, and 50 people will be randomized to receive an intravenous placebo. The&#xD;
      placebo will be in the form of 0.45% saline solution (&quot;half normal saline&quot;) and the alcohol&#xD;
      will be in the form of 6% volume/volume ethanol in 0.45% saline solution.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Actual">May 2020</completion_date>
  <primary_completion_date type="Actual">May 2019</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Atrial Fibrillation Induction</measure>
    <time_frame>This will be measured after study drug (ethanol or placebo) infusion. The measurement will be performed within 1 hour of the infusion.</time_frame>
    <description>Induction of Atrial fibrillation will be attempted by pacing and isoproterenol infusion following study drug infusion. The ability to induce atrial fibrillation (yes or no) will be recorded as the primary outcome.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Conduction Time</measure>
    <time_frame>This will be assessed during the experimental study from the Conduction Times that are measured before and after the study drug infusion. The measurements will be performed within 1 hour of the infusion.</time_frame>
    <description>The atrial conduction time will be measured before and after study drug infusion, and the difference between the two times will be recorded as the Change in Conduction Time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Atrial Effective Refractory Period (AERP)</measure>
    <time_frame>This will be assessed during the experimental study from the AERPs that are measured before and after the study drug infusion. The measurements will be performed within 1 hour of the infusion.</time_frame>
    <description>The AERP will be measured before and after study drug infusion, and the difference between the two times will be recorded as the Change in AERP</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Atrial Fibrillation</condition>
  <condition>Alcohol</condition>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Ethanol</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Ethanol</intervention_name>
    <description>6% volume/volume ethanol in 0.45% saline solution.</description>
    <arm_group_label>Ethanol</arm_group_label>
    <other_name>Alcohol</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>The placebo with be 0.45% saline solution (&quot;half normal saline&quot;).</description>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Saline</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients aged 21-80 with paroxysmal atrial fibrillation (AF), supraventricular&#xD;
             tachycardia, or undifferentiated palpitations who are to undergo either an elective&#xD;
             ablation procedure (for AF, atrial flutter, atria tachycardia, atrial ventricular&#xD;
             nodal reentrant tachycardia (AVNRT), or atrial ventricular reentrant tachycardia&#xD;
             (AVRT)) or a diagnostic electrophysiology study in order to diagnose and treat their&#xD;
             clinical arrhythmia at the University of California, San Francisco (UCSF) will be&#xD;
             eligible for enrollment.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
          -  Patients will be excluded if they are not in normal sinus rhythm (i.e. in AF, atrial&#xD;
             tachycardia, atrial flutter, or incessant AVNRT/AVRT) at the time of onset of the&#xD;
             procedure, any history of substance abuse or alcoholism as determined by history,&#xD;
             AUDIT questionnaire, or chart review, left ventricular ejection fraction &lt;50%,&#xD;
             inability to give informed consent, liver dysfunction (elevated aspartate&#xD;
             aminotransferase , alanine aminotransferase, total bilirubin, or alkaline phosphatase&#xD;
             &gt;2x normal), clinical evidence of liver disease (enlarged liver, caput medusa, spider&#xD;
             angiomas, or other signs of liver disease on exam), or pregnancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>81 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregory M Marcus, MD, MAS</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Jonathan W Dukes, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, San Francisco</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Marcus GM, Dukes JW, Vittinghoff E, Nah G, Badhwar N, Moss JD, Lee RJ, Lee BK, Tseng ZH, Walters TE, Vedantham V, Gladstone R, Fan S, Lee E, Fang C, Ogomori K, Hue T, Olgin JE, Scheinman MM, Hsia H, Ramchandani VA, Gerstenfeld EP. A Randomized, Double-Blind, Placebo-Controlled Trial of Intravenous Alcohol to Assess Changes in Atrial Electrophysiology. JACC Clin Electrophysiol. 2021 May;7(5):662-670. doi: 10.1016/j.jacep.2020.11.026. Epub 2021 Jan 27.</citation>
    <PMID>33516710</PMID>
  </results_reference>
  <verification_date>March 2021</verification_date>
  <study_first_submitted>September 30, 2013</study_first_submitted>
  <study_first_submitted_qc>November 26, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 27, 2013</study_first_posted>
  <results_first_submitted>February 3, 2021</results_first_submitted>
  <results_first_submitted_qc>March 12, 2021</results_first_submitted_qc>
  <results_first_posted type="Actual">March 16, 2021</results_first_posted>
  <last_update_submitted>March 12, 2021</last_update_submitted>
  <last_update_submitted_qc>March 12, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">March 16, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Atrial Fibrillation</keyword>
  <keyword>Alcohol</keyword>
  <keyword>Electrophysiologic properties of the atria</keyword>
  <keyword>Randomized Clinical Study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Atrial Fibrillation</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Ethanol</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>March 30, 2017</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT01996943/Prot_000.pdf</document_url>
    </provided_document>
    <provided_document>
      <document_type>Statistical Analysis Plan</document_type>
      <document_has_protocol>No</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>December 7, 2020</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/43/NCT01996943/SAP_001.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Placebo</title>
          <description>The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Placebo: The placebo with be 0.45% saline solution (&quot;half normal saline&quot;).</description>
        </group>
        <group group_id="P2">
          <title>Ethanol</title>
          <description>Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Ethanol: 6% volume/volume ethanol in 0.45% saline solution.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="50"/>
                <participants group_id="P2" count="50"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Placebo</title>
          <description>The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Placebo: The placebo with be 0.45% saline solution (&quot;half normal saline&quot;).</description>
        </group>
        <group group_id="B2">
          <title>Ethanol</title>
          <description>Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Ethanol: 6% volume/volume ethanol in 0.45% saline solution.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="50"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="100"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="34"/>
                    <measurement group_id="B3" value="62"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="22"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="38"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="61.14" spread="13.08"/>
                    <measurement group_id="B2" value="58.78" spread="11.27"/>
                    <measurement group_id="B3" value="60.51" spread="10.54"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="14"/>
                    <measurement group_id="B3" value="26"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="36"/>
                    <measurement group_id="B3" value="74"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="48"/>
                    <measurement group_id="B3" value="98"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="45"/>
                    <measurement group_id="B2" value="44"/>
                    <measurement group_id="B3" value="89"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="50"/>
                    <measurement group_id="B2" value="50"/>
                    <measurement group_id="B3" value="100"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Atrial Fibrillation Induction</title>
        <description>Induction of Atrial fibrillation will be attempted by pacing and isoproterenol infusion following study drug infusion. The ability to induce atrial fibrillation (yes or no) will be recorded as the primary outcome.</description>
        <time_frame>This will be measured after study drug (ethanol or placebo) infusion. The measurement will be performed within 1 hour of the infusion.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Placebo: The placebo with be 0.45% saline solution (&quot;half normal saline&quot;).</description>
          </group>
          <group group_id="O2">
            <title>Ethanol</title>
            <description>Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Ethanol: 6% volume/volume ethanol in 0.45% saline solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Atrial Fibrillation Induction</title>
          <description>Induction of Atrial fibrillation will be attempted by pacing and isoproterenol infusion following study drug infusion. The ability to induce atrial fibrillation (yes or no) will be recorded as the primary outcome.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="22"/>
                    <measurement group_id="O2" value="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Conduction Time</title>
        <description>The atrial conduction time will be measured before and after study drug infusion, and the difference between the two times will be recorded as the Change in Conduction Time</description>
        <time_frame>This will be assessed during the experimental study from the Conduction Times that are measured before and after the study drug infusion. The measurements will be performed within 1 hour of the infusion.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Placebo: The placebo with be 0.45% saline solution (&quot;half normal saline&quot;).</description>
          </group>
          <group group_id="O2">
            <title>Ethanol</title>
            <description>Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Ethanol: 6% volume/volume ethanol in 0.45% saline solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Conduction Time</title>
          <description>The atrial conduction time will be measured before and after study drug infusion, and the difference between the two times will be recorded as the Change in Conduction Time</description>
          <units>ms</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Paroximal coronary sinus (CSp) to high right atrium (hRA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.67" lower_limit="-1.33" upper_limit="2.67"/>
                    <measurement group_id="O2" value="0.33" lower_limit="-1.67" upper_limit="4.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CSp to Left upper pulmonary vein (LUPV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.50" lower_limit="-2.00" upper_limit="12.83"/>
                    <measurement group_id="O2" value="2.88" lower_limit="-3.33" upper_limit="9.17"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Distal coronary sinus (CSd) to CSp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" lower_limit="-1.00" upper_limit="3.00"/>
                    <measurement group_id="O2" value="0.33" lower_limit="-2.00" upper_limit="2.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hRA to His bundle (His)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.50" lower_limit="-2.50" upper_limit="10.67"/>
                    <measurement group_id="O2" value="-2.00" lower_limit="-5.00" upper_limit="1.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>hRA to low right atrium (lRA)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.50" lower_limit="-2.67" upper_limit="5.33"/>
                    <measurement group_id="O2" value="0.50" lower_limit="-2.67" upper_limit="5.33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>LUPV to right upper pulmonary vein (RUPV)</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.67" lower_limit="-9.67" upper_limit="14.83"/>
                    <measurement group_id="O2" value="3.33" lower_limit="-10.00" upper_limit="11.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUPV to CSd</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1" lower_limit="-6.00" upper_limit="7.67"/>
                    <measurement group_id="O2" value="2.33" lower_limit="-2.33" upper_limit="10.50"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>RUPV to His</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.33" lower_limit="-6.00" upper_limit="4.67"/>
                    <measurement group_id="O2" value="4.33" lower_limit="-4.00" upper_limit="11.00"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Atrial Effective Refractory Period (AERP)</title>
        <description>The AERP will be measured before and after study drug infusion, and the difference between the two times will be recorded as the Change in AERP</description>
        <time_frame>This will be assessed during the experimental study from the AERPs that are measured before and after the study drug infusion. The measurements will be performed within 1 hour of the infusion.</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Placebo</title>
            <description>The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Placebo: The placebo with be 0.45% saline solution (&quot;half normal saline&quot;).</description>
          </group>
          <group group_id="O2">
            <title>Ethanol</title>
            <description>Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Ethanol: 6% volume/volume ethanol in 0.45% saline solution.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Atrial Effective Refractory Period (AERP)</title>
          <description>The AERP will be measured before and after study drug infusion, and the difference between the two times will be recorded as the Change in AERP</description>
          <units>ms</units>
          <param>Mean</param>
          <dispersion>95% Confidence Interval</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="50"/>
                <count group_id="O2" value="50"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.59" lower_limit="-4.96" upper_limit="8.14"/>
                    <measurement group_id="O2" value="-3.35" lower_limit="-9.89" upper_limit="3.18"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>1 year post-ablation</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Placebo</title>
          <description>The placebo will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Placebo: The placebo with be 0.45% saline solution (&quot;half normal saline&quot;).</description>
        </group>
        <group group_id="E2">
          <title>Ethanol</title>
          <description>Ethanol (alcohol) will be administered to participants after the baseline electrophysiologic measurements are recorded.&#xD;
Ethanol: 6% volume/volume ethanol in 0.45% saline solution.</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Tamponade</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="50"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Gregory Marcus</name_or_title>
      <organization>University of California, San Francisco</organization>
      <phone>(415) 353-2554</phone>
      <email>Greg.Marcus@ucsf.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

